Center for Clinical Molecular Medicine.
Leuk Lymphoma. 2014 Mar;55(3):611-7. doi: 10.3109/10428194.2013.807924. Epub 2013 Jul 29.
The CD34+/CD38- immunophenotype is used to identify candidate hematopoietic stem cells (HSCs) and leukemia-initiating cells (LICs). However, the clinical significance of the CD34+/CD38-proportion in childhood acute lymphoblastic leukemia (ALL) is not well established. Here, we found that a high proportion of CD34+/CD38- cells from 112 patients with childhood ALL was negatively correlated with the outcome. Also the percentage of CD34+/CD38- cells was associated with clinical and biological features of patients with ALL. Further, a high proportion of CD34+/CD38- cells in childhood ALL was positively correlated with advanced risk subgroups, which could predict risk stratification by receiver operating characteristic (ROC) curve analysis. In addition, a larger tumor burden and lower survival rate were observed in mice injected with CD34+/CD38- cells, but not in mice injected with other fractions. Our data reveal that a high proportion of CD34+/CD38- cells is positively associated with a poor prognosis of childhood ALL, to further guide therapy of the disease.
CD34+/CD38- 免疫表型用于鉴定候选造血干细胞 (HSCs) 和白血病起始细胞 (LICs)。然而，CD34+/CD38- 比例在儿童急性淋巴细胞白血病 (ALL) 中的临床意义尚未得到充分确立。在这里，我们发现 112 例儿童 ALL 患者的 CD34+/CD38- 细胞比例较高与预后不良呈负相关。此外，CD34+/CD38- 细胞的比例与 ALL 患者的临床和生物学特征相关。进一步的，儿童 ALL 中 CD34+/CD38- 细胞的高比例与高级别风险亚组呈正相关，通过接收者操作特征 (ROC) 曲线分析可以预测风险分层。此外，在注射 CD34+/CD38- 细胞的小鼠中观察到更大的肿瘤负担和更低的生存率，但在注射其他细胞亚群的小鼠中没有观察到。我们的数据表明，CD34+/CD38- 细胞的高比例与儿童 ALL 的预后不良呈正相关，进一步指导疾病的治疗。
